#Upadacitinib rises ‘ Up’ in all subgroups of #GCA Subset of overall #RCT of #rinvoq w more reduction of #steroids vs placebo+ slower #prednisone taper Consistent results best in UPA 15 mg >UPA 7.5mg/d > #placebo #ACR24 #ACRBest @RheumNow @ACRheum abst#1695 https://t.co/dA7RkNmWFd

Alright help me out here; this is pretty implausible, right? Why would be pts be 11% more adherent to UPA? What's the bio-plausibility here? UPA 10% better than other JAKs? Could do a network meta analysis; betting this doens't replicate #ACR24 @RheumNow Abstr#1362 https://t.co/vpPq3vu9Wf

#Rheumatoid #arthritis is an independent risk factor for death in nonmetastatic clear cell renal ca ! 👇N=32K, 802 w RA also Caveats immunotherapy Offered = in RA Cancer specific mortality not affected By #RA Frailty & RA affected outcomes #ACR24 @RheumNow @ACRheum #1327 https://t.co/rAQ57BPA19

The Joint Project is a community-based, barangay health worker-led screening program that aims to increase MSK dse awareness, timely referral & treatment or rehab. The figure below illustrates the conceptual framework for the program @RheumNow #ACR24 abs0979 https://t.co/yxXsASl2GJ

This study by Dr. UGazel et al shows that cervical DISH in SpA is similar to the general population. Of note, HLAB27+ axSpA pts had more DISH while PsA pts had DISH if they were HLaB27(-) @RheumNow #ACR24 abs1447 https://t.co/GtcvxVSb8B

Gonzalez Molina et al. MANHATTAN observational study. In PsA after 1st TNFi failure should we use guselkumab or 2nd TNFi? Guselkumab slightly better persistence, DAPSA, and improvements in joint counts. @RheumNow #ACR24 Abstr#1469 https://t.co/X3TMCVys6B https://t.co/vvkUYbzVDq

Ultrasound guided injections on cadavers improve rheumatology trainees ability to do #joint #injections 17 trainees -a couple of hrs of cadaver inj ▶️ joint injection confidence improved esp uncommon / difficult areas Elbow Ankle Wrist @RheumNow #ACR24 @ACRheum abst#1310 https://t.co/ZcER4s8QcR

No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/IOzckJIfYf https://t.co/8S6FnffVLG

TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data Glad to see this is headed straight to a Phase 3! Hoping they allow IVIG: has been a problem with many/most/all? recent dermato studies #ACR24 @RheumNow Abstr#0882 https://t.co/KS8fTMBpPR

Kharouf et al. Secondary biologic failure in PsA common - 36% over 5 years. Predictors - higher baseline SJC HR 1.39 and PASI HR 1.14. TNFi did better, HR 0.40, esp golimumab - but ?this as often used as first bDMARD? @RheumNow #ACR24 Abstr#1455 https://t.co/ET0WX6tKMr https://t.co/iVcCkM0hu3